12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersLongeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. vTv Therapeutics (NASDAQ:VTVT) stock i
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
WESTON, Fla., May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening m
Shareholders in VTv Therapeutics (NASDAQ:VTVT) Are in the Red If They Invested Three Years Ago
Cantex Pharmaceuticals Receives FDA Orphan Drug Designation for Its Pancreatic Cancer Treatment
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...
Express News | VTv Therapeutics Inc - Net Loss Attributable to vTv Shareholders for Three Months Ended March 31, 2024, Was $4.9 Mln or $1.17 per Basic Share
Express News | VTv Therapeutics Q1 Operating Income USD -5.627 Million
Express News | VTv Therapeutics Q1 Operating Expenses USD 6.627 Million
vTv Therapeutics | 10-Q: Quarterly report
Express News | VTv Therapeutics Inc - Qtrly Revenue $1 Mln
Express News | VTv Therapeutics Inc - Qtrly Net Loss Attributable $1.17 per Basic Share
VTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
PDF Version HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy
VTv Therapeutics Files $250M Mixed Securities Shelf
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...
VTv Therapeutics Appoints Anne Phillips, Reshuffles Board Committees
Express News | VTv Therapeutics Q4 EPS $(1.67) Up From $(2.28) YoY
VTv Therapeutics 4Q Loss/Shr $1.67 >VTVT
VTv Therapeutics 4Q Loss/Shr $1.67 >VTVT
Press Release: VTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update -- Recently completed $51 million PIPE from healthcare-focused institutional inve
VTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
PDF Version Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund. Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adju
No Data